Nasus Pharma Ltd. (NSRX)
NYSE American
Price as at 30 Sept 2026, 21:54 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nasus Pharma Ltd. trades at $3.69. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its NSRX data?
Fundamentals for NSRX come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:54 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NSRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.